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A B S T R A C T
Background
Intubation is associated with bacterial colonisation of the respiratory tract and therefore may increase the risk of acquiring an infection.
The infection may prolong the need for mechanical ventilation and increase the risk of chronic lung disease. The use of prophylactic
antibiotics has been advocated for all mechanically ventilated newborns in order to reduce the risk of colonisation and the acquisition
of infection. However, there is the possibility that the harm this may cause might outweigh the benefit.
Objectives
To assess the effects of prophylactic antibiotics on mortality and morbidity in intubated, ventilated newborn infants who are not known
to have infection. In separate comparisons, two different policies regarding the prophylactic use of antibiotics in intubated, ventilated
infants were reviewed:
1) among infants who have been intubated for mechanical ventilation, a policy of prophylactic antibiotics for the duration of intubation
versus placebo or no treatment
2) among intubated, ventilated infants who have been started on antibiotics at the time of intubation but whose initial cultures to rule
out sepsis were negative, a policy of continuing versus discontinuing prophylactic antibiotics
Search methods
MEDLINE (January 1950 toMarch 2007), CINAHL (1982 to March 2007), the Cochrane Central Register of Controlled Trials (The
Cochrane Library, Issue 1, 2007), the Cochrane Neonatal Group Specialised Register and reference lists of articles were searched. This
search was updated in November 2010.
Selection criteria
Randomised controlled trials of sufficient quality in which mechanically ventilated newborn infants are randomised to receive prophy-
lactic antibiotics versus placebo or no treatment.
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Data collection and analysis
Two reviewers independently assessed trial quality.
Main results
Two studies met the criteria for inclusion in this review. One was of insufficient quality to draw any meaningful conclusions. The
other was of fair quality and found no significant differences between treatment and control groups in any of the reported outcomes,
however, the rates of septicaemia were not reported.
Authors’ conclusions
There is insufficient evidence from randomised trials to support or refute the use of prophylactic antibiotics when starting mechanical
ventilation innewborn infants, or to support or refute continuing antibiotics once initial cultures have ruled out infection inmechanically
ventilated newborn infants.
P L A I N L A N G U A G E S U M M A R Y
Prophylactic antibiotics to reduce morbidity and mortality in ventilated newborn infants
There is insufficient evidence from randomised trials to either support or refute the routine use of preventive antibiotics in newborn
babies with breathing tubes in place. Newborn babies occasionally require a tube in the windpipe to help them breathe. The use of
a breathing may cause the baby to develop an infection and become sick. Some people believe that antibiotics should be given to all
babies with breathing tubes in order to reduce the chance of an infection occurring. However, antibiotics can have unwanted effects.
It is possible that these effects might be worse than any benefit gained. The reviewers found insufficient evidence to either support or
refute the routine use of antibiotics for all babies with breathing tubes.
B A C K G R O U N D
Description of the condition
Endotracheal intubation and mechanical ventilation are com-
monly used in the management of newborn infants with res-
piratory distress and other potentially life-threatening disorders.
Studies in infants and in older patients have shown that bacterial
colonisation of the respiratory tract is associated with intubation
(da Silva 1999; Rubenstein 1992; Pellinen 1983). There is evi-
dence that rates of colonisation increase with duration of intuba-
tion (Friedland 2001). Colonisation of the airway may increase
the risk of acquiring various infections including pneumonia and
tracheitis. Rubenstein et al (Rubenstein 1992) showed that buccal
mucosa colonisation is frequently an antecedent to endotracheal
colonisation. Bacterial colonisation and/or infection of the respi-
ratory tract may prolong the need for mechanical ventilation and
increase the risk of chronic lung disease (Young 2005).
Mechanisms by which endotracheal intubation may allow lower
respiratory infection to develop include: upper airway defences be-
ing bypassed, reduced cough reflex, the endotracheal tube (ETT)
acting as a reservoir of bacteria, and the ETT causing direct injury
to the mucosa thereby creating binding sites for bacteria. Also,
patients requiring intubation may, by virtue of their underlying
illness, have impaired defence mechanisms - both local and sys-
temic. Prematurity is recognised as a risk factor for late onset sepsis
(Dear 1999).
Description of the intervention
Although the evidence is not clear, it is common practice in neona-
tal units to institute antibiotics in infants with respiratory distress.
What is less clear is when these antibiotics should be discontinued
if no infection is proven.
How the intervention might work
It has been advocated that if the infant should require ongoing
mechanical ventilation then antibiotics should be continued in or-
der to reduce the rate of colonisation of the endotracheal tube and
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thereby reduce the risk of acquired infection (Greenough 1999).
However, prophylactic antibiotics may not prevent colonisation
and/or infection and, therefore,may not decrease infection-related
morbidity and mortality. Also, any policy of prophylactic antibi-
otic use should take into account the possibility of encouraging
increased resistance among pathogenic bacteria (Dear 1999).
Why it is important to do this review
This review updates the existing review of ’Prophylactic antibiotics
to reduce morbidity and mortality in ventilated newborn infants’
which was published in the Cochrane Library Issue 1, 2004 (Inglis
2004).
O B J E C T I V E S
The primary objective was to assess the effect of prophylactic an-
tibiotics on mortality and morbidity in intubated, ventilated new-
born infants who are not known to have infection.
In separate comparisons, two different policies regarding the pro-
phylactic use of antibiotics in intubated, ventilated infants were
reviewed:
1) among infants who were being intubated for mechanical venti-
lation, a policy of prophylactic antibiotics for the duration of intu-
bation versus placebo or no treatment. This addresses the question
of whether or not infants who are being intubated and ventilated,
who do not have clinical or laboratory evidence of infection at
that time, should be routinely started on antibiotics at the time of
intubation.
2) among intubated, ventilated infants who were started on antibi-
otics at the time of intubation but whose initial cultures to rule our
sepsis were negative, a policy of continuing versus discontinuing
prophylactic antibiotics. This addresses the question of whether
or not antibiotics should routinely be stopped at the time initial
cultures to evaluate for possible infection are reported as negative.
Data permitting, subgroup analyses were planned to determine
whether results differ by:
gestational age (e.g., preterm versus term, < 28 weeks gestational
age (GA) or not, < 32 weeks GA or not); type of antibiotic (e.g.,
penicillins, macrolides, aminoglycosides, cephalosporins, or com-
binations).
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials and some non-randomised con-
trolled trials (i.e., quasi-randomised trials) in which individual
newborn infants were randomised to receive prophylactic antibi-
otics versus placebo or no treatment. Cross-over studies were not
included in this review.
Types of participants
Intubated newborn infants whowere not known to have infection:
full term infants less than 28 days old and preterm infants up to 44
weeks postmenstrual age. Age criteria were to be fulfilled at time
of initial intubation and/or treatment allocation.
Types of interventions
Any antibiotic, or combination of antibiotics, versus placebo or no
treatment. This could include: 1) a policy of all intubated infants
having antibiotics compared with placebo or no treatment; or 2) a
policy of intubated infants continuing on antibiotics once initial
cultures to rule out sepsis were negative compared with placebo
or ceasing antibiotics.
Types of outcome measures
Primary outcomes
• Mortality (neonatal, at hospital discharge, or at one year, 18
months, two years, or five years).
• Chronic lung disease (oxygen requirement at 36 weeks
postmenstrual age.
Secondary outcomes
• Septicaemia (blood culture positive, or however defined in
individual studies).
• Duration of ventilation (hours or days).
• Duration of respiratory support (hours or days).
• Duration of oxygen therapy (hours or days).
• Duration of hospital stay (days).
• Neurodevelopmental outcome (cerebral palsy, sensorineural
hearing loss, visual impairment and/or developmental delay at
one year, 18 months, two years, or five years).
Search methods for identification of studies
The standard search strategy for the Cochrane Neonatal Review
Group was used. Searches were made of MEDLINE from 1950 to
March 2007 (Table 1),CINAHL from1982 toMarch 2007 (Table
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2), the Cochrane Central Register of Controlled Trials (CEN-
TRAL, The Cochrane Library, Issue 1, 2007) (Table 3) using the
following strategy:
MeSH search terms “Intubation, intratracheal” OR “Respiration,
artificial” OR the textwords “ventilat$” OR “intubat$” OR “en-
dotracheal” OR “endo-tracheal” OR “intra-tracheal” OR “intra-
tracheal” OR “ETT”,
AND
MeSH search term “Infant, newborn” OR the textwords
“neonat$” OR “infant”’
AND
MeSH search term “Anti-Bacterial Agents” OR the textword “an-
tibiotic”
AND
MeSH search terms “Chemoprevention” OR “Antibiotic Prophy-
laxis” OR the textword “prophyl$”.
We also searched previous reviews (including cross references),
abstracts, and conference and symposia proceedings. Searches were
not restricted to publications in the English language or published
data.
Using the above search strategy, nine studies were identified for
possible inclusion. Two controlled trials (Harris 1976; Lyon 1998)
were judged as eligible for inclusion in this review. Citations to
these studies were searched for in the Science Citation Index (the
ISI Web of Science, Science Citation Index - SCI-EXPANDED,
SSCI, A&HCI). No additional studies for inclusion were found.
Seven studies were excluded from the review. Three were not
randomised or quasi-randomised controlled trials (Brown 1996;
Krishnan 1995; Papoff 1997), and four were excluded on the basis
of wrong intervention (Adhikari 1996 - immunoglobulin used as
prophylaxis) or wrong population (Jonsson 1998 - only studied
those infants known to have respiratory colonisation; Kicklighter
2001 - was not restricted to infants with endotracheal tubes;
Mandelli 1989 - studied children and adults).
In November 2010 we updated the search as follows: MEDLINE
(search via PubMed), CINAHL, EMBASE and CENTRAL (The
Cochrane Library) were searched from 2007 to 2010. Search terms:
(Intubation, intratracheal OR Respiration, artificial OR venti-
lat* OR intubat* OR endotracheal OR endo-tracheal OR intra-
tracheal OR intratracheal OR ETT) and (anti-bacterial agents
OR antibiotic) and (chemoprevention OR antibiotic prophy-
laxis OR prophyl*) AND ((infant, newborn[MeSH] OR new-
born OR neon* OR neonate OR neonatal OR premature OR low
birth weight OR vlbw OR LBW) AND (randomized controlled
trial[pt] OR controlled clinical trial[pt] OR randomized[tiab] OR
placebo[tiab] OR clinical trials as topic[mesh] OR randomly[tiab]
OR trial[ti]) NOT (animals[mh] NOT humans[mh]))
In November 2010 clinicaltrials.gov and controlled-trials.com
were also searched for relevant studies.
Data collection and analysis
Data collection and analysis was performed in accordance with
the recommendations of the Cochrane Neonatal Review Group.
Selection of studies
All randomised and quasi-randomised controlled trials fulfilling
the selection criteria described in the previous section were in-
cluded.Two of the review authors worked independently to search
for and assess trials for inclusion and methodological quality. The
review authors resolved any disagreement by discussion.
Data extraction and management
The review authors extracted data independently.Differences were
resolved by discussion. The first author of the study by Harris et
al (Harris 1976) and the first author of the study by Lyon et al
(Lyon 1998) could not be contacted for further information.
Assessment of risk of bias in included studies
The methodological quality of the included studies were assessed
using the following key criteria: allocation concealment (blinding
of randomisation), blinding of intervention, completeness of fol-
low-up, and blinding of outcome measurement/assessment. For
each criterion, assessment was yes, no, can’t tell. Two review au-
thors separately assessed each study. Any disagreementwas resolved
by discussion. This information was added to the Characteristics
of Included Studies table.
In addition, for the update in 2010, the following issues were
evaluated and entered into the Risk of Bias table:
1) Sequence generation (checking for possible selection bias). Was
the allocation sequence adequately generated? For each included
study, we categorized the method used to generate the allocation
sequence as:
- adequate (any truly random process e.g. random number table;
computer random number generator);
- inadequate (any non random process e.g. odd or even date of
birth; hospital or clinic record number);
- unclear.
(2) Allocation concealment (checking for possible selection bias).
Was allocation adequately concealed? For each included study, we
categorized the method used to conceal the allocation sequence
as:
- adequate (e.g. telephone or central randomisation; consecutively
numbered sealed opaque envelopes);
- inadequate (open random allocation; unsealed or non-opaque
envelopes, alternation; date of birth);
- unclear.
(3) Blinding (checking for possible performance bias). Was knowl-
edge of the allocated intervention adequately prevented during the
study? At study entry? At the time of outcome assessment? For
each included study, we categorized the methods used to blind
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study participants and personnel from knowledge of which in-
tervention a participant received. Blinding was assessed separately
for different outcomes or classes of outcomes. We categorized the
methods as:
- adequate, inadequate or unclear for participants;
- adequate, inadequate or unclear for personnel;
- adequate, inadequate or unclear for outcome assessors.
In some situations there may be partial blinding e.g. where out-
comes are self-reported by unblinded participants but they are
recorded by blinded personnel without knowledge of group as-
signment. Where needed “partial” was added to the list of options
for assessing quality of blinding.
(4) Incomplete outcome data (checking for possible attrition bias
through withdrawals, dropouts, protocol deviations). Were in-
complete outcome data adequately addressed? For each included
study and for each outcome, we described the completeness of
data including attrition and exclusions from the analysis.We noted
whether attrition and exclusions were reported, the numbers in-
cluded in the analysis at each stage (compared with the total ran-
domized participants), reasons for attrition or exclusion where re-
ported, and whether missing data were balanced across groups or
were related to outcomes. Where sufficient information was re-
ported or supplied by the trial authors, we re-included missing
data in the analyses. We categorized the methods as:
- adequate (< 20% missing data);
- inadequate (≥ 20% missing data):
- unclear.
(5) Selective reporting bias. Are reports of the study free of sugges-
tion of selective outcome reporting? For each included study, we
described how we investigated the possibility of selective outcome
reporting bias and what we found. We assessed the methods as:
- adequate (where it is clear that all of the study’s pre-specified
outcomes and all expected outcomes of interest to the review have
been reported);
- inadequate (where not all the study’s pre-specified outcomes have
been reported; one or more reported primary outcomes were not
pre-specified; outcomes of interest are reported incompletely and
so cannot be used; study fails to include results of a key outcome
that would have been expected to have been reported);
- unclear.
(6) Other sources of bias. Was the study apparently free of other
problems that could put it at a high risk of bias?
For each included study, we described any important concerns we
had about other possible sources of bias (for example, whether
there was a potential source of bias related to the specific study
design or whether the trial was stopped early due to some data-
dependent process). We assessed whether each study was free of
other problems that could put it at risk of bias as:
- yes; no; or unclear.
If needed, we planned to explore the impact of the level of bias
through undertaking sensitivity analyses.
Measures of treatment effect
Analysis of individual trials: For continuous variables such as du-
ration of oxygen therapy, mean differences, and 95% confidence
intervals were to be reported. For categorical outcomes such as
mortality, the relative risks (RR) and 95% confidence intervals
were to be reported.
Assessment of heterogeneity
We planned to estimate the treatment effects of individual trials
and examine heterogeneity between trials by inspecting the for-
est plots and quantifying the impact of heterogeneity using the I
2 statistic. If we detected statistical heterogeneity, we planned to
explore the possible causes (for example, differences in study qual-
ity, participants, intervention regimens, or outcome assessments)
using post hoc sub group analyses. We planned to use a fixed ef-
fects model for meta-analysis.
Data synthesis
Pooled results: For continuous variables, weighted mean differ-
ences (WMD) and 95% confidence intervals were to be reported.
For categorical outcomes, the relative risks (RR) and 95% confi-
dence intervals were to be reported. For significant findings, the
risk difference (RD) and number needed to treat (NNT) were also
to be reported. Each treatment effect was to be tested for hetero-
geneity to help determine suitability for pooling of results in a
meta-analysis. The fixed effects model was to be used for meta-
analysis.
Subgroup analysis and investigation of heterogeneity
Data permitting, subgroup analyses were planned to determine
whether results differ by:
gestational age (e.g., preterm versus term, < 28 weeks gestational
age (GA) or not, < 32 weeks GA or not); type of antibiotic (e.g.,
penicillins, macrolides, aminoglycosides, cephalosporins, or com-
binations).
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
Harris et al (Harris 1976) attempted to address the question of
whether or not infants who were being intubated and ventilated
and who do not have clinical or laboratory evidence of infection at
that time should be routinely started on antibiotics at the time of
5Prophylactic antibiotics to reduce morbidity and mortality in ventilated newborn infants (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
intubation. They performed a randomised study comparing an-
tibiotic usage fromwithin four hours of intubation with antibiotic
usage only on the basis of evidence of infection. Fifty-four infants
were studied (32 in the study group and 22 in the control group).
Respiratory tract colonisation and systemic infection were assessed
by regular cultures of blood and tracheal aspirates. Results were
presented as rates of initial colonisation and infection; subsequent
infection in initially colonised infants; and subsequent colonisa-
tion and infection in initially uncolonised infants. Colonising or-
ganisms were compared with infecting organisms. The only out-
come that was considered clinically relevant for which data was
presented were rates of infection.
Lyon et al (Lyon 1998) attempted to address the question of
whether or not treatment with erythromycin from birth would
reduce the inflammatory response and thereby influence the inci-
dence and severity of subsequent chronic lung disease in infants
at high risk of developing chronic lung disease. They performed
a randomised trial of intravenous erythromycin for seven days vs.
no treatment in ventilated babies less than or equal to 30 weeks
gestation. Seventy-five infants were enrolled (treatment group =
34, control group = 41). The primary outcome was levels of in-
flammatory cytokines in the lungs. Other clinically relevant out-
comes included mortality, chronic lung disease, length of stay, and
time on a ventilator.
Risk of bias in included studies
Harris et al (Harris 1976) performed a small randomised con-
trolled trial of prophylactic antibiotics versus antibiotics for treat-
ment of infection in intubated and ventilated newborn infants.
Only a small proportion of the total number of ventilated infants
were eligible for inclusion in the study due to prior administration
of antibiotics. It is unknown whether allocation and outcome as-
sessment were blind. Administration of the intervention did not
appear to be done in a blinded fashion. Twenty-eight percent of
enrolled infants were either lost to follow up or not analysed by
allocated group (i.e. intention to treat). Nine infants were found
to have infection at enrolment but data on their group allocation
were not provided and it is not clear how these infants were treated
prior to the time that the systemic culture results became available.
The methodological quality of the trial performed by Lyon et al
(Lyon 1998) was fair. Allocation concealment was achieved by use
of sealed envelopes. The intervention was not blinded. Assessment
of the primary outcome assessment was blinded. Most of the sec-
ondary outcomes appeared not to have been blinded, although
this was not specifically stated. Follow up for the reported out-
comes was 100%. Some clinically important outcomes (i.e., septi-
caemia and neurodevelopmental outcome) were not reported, nor
did they report whether other antibiotics were used in any subjects
during the study period.
Effects of interventions
Two studies (Harris 1976; Lyon 1998, described above) were
found for inclusion in this review. However, given the poor
methodological quality of the study by Harris et al (Harris 1976),
the results obtained with respect to the effects on infection rate
cannot be relied upon. No data on any other clinically relevant
outcomes were given. Lyon et al (Lyon 1998) found no significant
differences between treatment and control groups in any of the re-
ported outcomes. They did not report rates of septicaemia. Given
the significant differences in methodology and reported outcomes
of the two studies, meta-analysis was not done.
(See Table, Characteristics of included studies)
D I S C U S S I O N
This review has attempted to determine whether prophylactic an-
tibiotics are warranted in mechanically ventilated newborns. Two
different circumstances were evaluated:
1. Should infants who are intubated and ventilated be routinely
started on antibiotics at the time of intubation?
2. Should infants who are intubated and ventilated, and who are
started on antibiotics pending investigation results be continued
on prophylactic antibiotics after the investigations have ruled out
infection?
A major limiting factor in trying to determine the role of prophy-
lactic antibiotics in mechanically ventilated newborns is that it is
likely that most newborn infants who are mechanically ventilated
will receive antibiotic treatment.Newborn infants with respiratory
problems (e.g., respiratory distress, apnoea) are usually started on
antibiotics at the same time that they are intubated because such
problems may also indicate the presence of infection. Because the
majority of ventilated newborns are treated in this way, the first
scenario described above would be relevant to relatively few me-
chanically ventilated newborns.
Only two studies were found that attempted to answer the ques-
tion of whether infants who are intubated and ventilated should
be routinely started on antibiotics. The two studies were very dif-
ferent in methodological quality, intervention and reported out-
comes, which made pooling of results impractical. Harris et al
(Harris 1976) demonstrated a statistically significant reduction in
infection rate in the treatment compared to the control group, but
the data were not included in this review because of the study’s
poor methodological quality. Since this study was reported, the
nature and practice of neonatal medicine has changed consider-
ably. For these reasons, the results of this study cannot be used to
guide current practice. It is also difficult to use the results of the
study by Lyon et al (Lyon 1998) to guide current practice as the
intervention used was narrow-spectrum and intended to influence
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the role that Ureaplasma urealyticum plays in the development of
chronic lung disease. The study was underpowered to detect im-
portant differences for the outcomes of death or chronic lung dis-
ease. They did not report rates of systemic infection, which was a
planned primary outcome of this review. It remains possible that
other colonising or infecting organisms may play an important
role in determining morbidity and mortality in ventilated new-
born infants.
No studies were found that addressed the question of whether in-
fants who are intubated and ventilated should be continued on
prophylactic antibiotics after investigations have ruled out infec-
tion.
In order to justify the use of prophylactic antibiotics (rather than
treatment of infection) in mechanically ventilated infants there
should be evidence that the benefit outweighs the harm. This
should include an adequate assessment not only of short term
outcomes such as infection rate and duration of ventilation, but
also of long term outcomes such as mortality, long term respi-
ratory morbidity and neurodevelopmental outcome. Harris et al
(Harris 1976) reported a reduction in rates of colonisation and
infection with the use of prophylactic antibiotics, while Lyon et al
(Lyon 1998) reported no significant effect in some short term out-
comes using targeted prophylaxis. No long term outcomeswere re-
ported in either of the included studies. Harris et al (Harris 1976)
found that gram negative bacteria were very common isolates from
colonised and infected infants. However, in a large cohort of ven-
tilated infants Cordero et al (Cordero 2000) demonstrated that
systemic antibiotics were inconsistent in eradicating gram negative
bacilli from the airway, and therefore they did not recommend the
use antibiotic prophylaxis or treatment of endotracheal colonisa-
tion.
Theoretical concerns about the potential harms of prophylactic an-
tibiotic use include antibiotic resistance, superinfection and drug
toxicity. Altered antibiotic resistance patterns may be of conse-
quence not only to the individual in whom prophylactic antibi-
otics are used but also to other patients within the hospital setting
and in the wider community at large.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
• There is insufficient evidence from randomised trials to
support or refute the use of prophylactic antibiotics when
starting mechanical ventilation in newborn infants.
• There is no evidence from randomised trials to support or
refute continuing antibiotics once initial cultures have ruled out
infection in mechanically ventilated newborn infants.
Implications for research
• If prophylactic antibiotics are to be considered when
starting mechanical ventilation then good quality randomised
controlled trials are required to show that their benefits outweigh
the harms. Unfortunately, almost all newborn infants who are
mechanically ventilated are likely to receive antibiotics to cover
possible infection and a randomised controlled trial may not be
practicable.
• A more pressing question is whether infants who initially
receive antibiotics for presumed infection should be continued
on antibiotics once initial cultures rule out infection. Good
quality randomised controlled trials are required to address this
issue.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Harris 1976
Methods Enrolled infants were assigned by random card draw to a study group (receiving antibi-
otics initially within 4 hours of intubation) and a control group (for whom antibiotics
were provided only on the basis of clinical or bacteriological findings suggesting infec-
tion). Respiratory tract colonisation was assessed by obtaining nasopharyngeal cultures
and tracheal aspirate cultures, and defined as the isolation of any potential pathogenic
organism from either site. Only Staphylococcus epidermidis and diphtheroids were de-
fined as non-pathogenic. Systemic infection was monitored by blood culture obtained
initially and every 3 days, and by concurrent CSF and suprapubic urine cultures when-
ever possible; and defined as isolation of any organism from blood, CSF or urine.
Blinding of randomisation: Unclear
Blinding of intervention: Probably no
Complete follow-up: No
Blinding of outcome assessment: Unclear
Participants University of Alabama, Birmingham, Alabama. Fifty-four newborn infants requiring
orotracheal intubation for more than 30 minutes for ventilatory support and who had
received no prior antibiotic therapy were enrolled. There were 32 in the study group and
22 in the control group. There were no significant differences between groups in regard
to birthweight, gestational age, race, sex, inborn versus outborn infants, or indication for
intubation. The most common indication for intubation was apnoea (n=35) followed
by hypercapnia (n=11) and for provision of continuous positive airway pressure (n=8)
Interventions Each infant in the study group received: 1) gentamicin, and 2) penicillin if inborn, or





Initial colonisation: twenty-three infants (43%) were colonised at the time of intubation.
This was significantly more common in those requiring intubation 12 or more hours
after birth.
Initial infection: of those initially colonised, 9 (39%) were infected. This finding was
significantly more common in those requiring intubation 12 or more hours after birth.
No infant without initial colonisation was found to have initial infection.
Subsequent colonisation: of the 31 infants without initial colonisation, 8 of 16 (50%) in
the study group and 11 of 15 (73%) in the control group subsequently became colonised
(p<0.05). This was significantly more common in those intubated for more than 72
hours and in those reintubated 2 or more times.
Subsequent infection: of those initially colonised but not infected, 2 of 9 (22%) in the
study group and 2 of 4 (50%) in the control group developed infection. Of those who
developed subsequent colonisation, 2 of 7 (29%) in the study group and 6 of 9 (67%)
in the control group developed infection. In total, 21 of 38 (55%) colonised infants
developed infection, while infection did not occur in any of the 10 infants who remained
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Harris 1976 (Continued)
uncolonised. It is also noted that in 1 case of systemic infection the infecting organism
was not isolated from nasopharyngeal or tracheal aspirate cultures. It is noted in the
discussion that mortality was not reduced in the study group.
Infants at highest risk of colonisation and infection were those intubated 12 or more
hours after birth, those intubated formore than72hours, and thosewhowere reintubated
2 or more times
Notes Six infants were lost from the study due to failure to obtain appropriate systemic cultures.
In total, 28% were lost to follow up or not analysed by group allocation. It is unclear
whether allocation or outcome assessment were blind. Intervention did not appear to be
blind
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk Enrolled infants were assigned by random
card draw to a study group (receiving an-
tibiotics initially within 4 hours of intuba-
tion) and a control group (for whom an-
tibiotics were provided only on the basis of
clinical or bacteriological findings suggest-
ing infection)
Allocation concealment? Unclear risk Blinding of randomisation: Unclear
Blinding?
All outcomes
High risk Blinding of intervention: Probably no
Blinding of outcome assessment: Unclear
Incomplete outcome data addressed?
All outcomes
High risk Complete follow-up: No
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Lyon 1998
Methods Enrolled infants were randomised (using sealed envelopes containing randomnumber ta-
ble allocation) to a study group (receivingprophylactic erythromycin) and a control group
(no treatment or placebo). Enrolment occurred at birth. On admission, tracheobronchial
secretions were collected for culture for common pathogens and polymerase chain reac-
tion (PCR) detection of Ureaplasma urealyticum. Bronchoalveolar lavage (BAL) fluid,
collected soon after admission, was assayed for interleukin-1 beta (IL-1beta), interleukin-
8 (IL-8) and tumour necrosis factor alpha (TNF-alpha) levels, as well as for differential
cell counts. The clinical teamwas blinded to the results of all of these investigations until
after completion of the study. BAL was repeated daily for five days if the baby was still
ventilated. Chronic lung disease (CLD) was defined as a persistent oxygen requirement
with chest radiograph changes at 36 weeks of gestational age. The primary outcome of
the study was to compare concentrations of the inflammatory cytokines in the treated
and control groups.
Blinding of randomisation: Yes
Blinding of intervention: No
Complete follow-up: Yes
Blinding of outcome assessment: For the primary outcome and for some secondary
outcomes (BAL differential cell counts, tracheobronchial secretion culture and PCR),
yes. For some secondary outcomes (length of stay, time on ventilator, CLD, mortality,
alveolar arterial oxygen difference (AaDO2) measured at 36 weeks while breathing 50%
oxygen), not stated
Participants Single neonatal unit - Edinburgh, UK. Eligibility criteria: newborn infants less than
or equal to 30 weeks of gestation and ventilated. Exclusion criteria: major congenital
abnormalities, early death or likely early death, surfactant given prior to enrolment,
positive culture (specimen not stated). 75 infants were enrolled (treatment group = 34,
control group = 41). There were significantly fewer male infants in the treatment group
(17 vs 30, P = 0.04). Median birthweight was 1032.5g in the treatment group and 1050g
in the control group. Median gestation was 28 weeks in the treatment group and 29
weeks in the control group
Interventions Each infant in the study group received erythromycin 15mg/kg/dose three times a day
intravenously for 7 days
Outcomes There were no significant differences at any time between the groups for IL-1beta or
IL-8 concentrations. TNF-alpha was almost undetectable in all samples.There were no
significant differences between the groups in BAL differential cell counts on any of the
days. There were no significant differences between groups in mortality, CLD, length of
stay, time on ventilator or AaDO2
Notes Outcomes of continuous variables were presented as medians and ranges. We attempted,
unsuccessfully, to contact the first author of this study
Risk of bias
Bias Authors’ judgement Support for judgement
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Lyon 1998 (Continued)
Adequate sequence generation? Unclear risk Enrolled infants were randomised (using
sealed envelopes containing random num-
ber table allocation) to a study group (re-
ceiving prophylactic erythromycin) and a
control group (no treatment or placebo).
Enrolment occurred at birth
Allocation concealment? Low risk Blinding of randomisation: Yes
Blinding?
All outcomes
High risk Blinding of intervention: No
Blinding of outcome assessment: For the
primary outcome and for some secondary
outcomes (BAL differential cell counts, tra-
cheobronchial secretion culture and PCR),
yes. For some secondary outcomes (length
of stay, time on ventilator, CLD, mor-
tality, alveolar arterial oxygen difference
(AaDO2) measured at 36 weeks while
breathing 50% oxygen), not stated
Incomplete outcome data addressed?
All outcomes
Low risk Complete follow-up: Yes
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Adhikari 1996 Wrong intervention - a randomised controlled trial of immunoglobulin prophylaxis, not antibiotic prophylaxis
Ballard 2007 Wrong population (was not restricted to infants with endotracheal tubes)
Brown 1996 Not a randomised controlled trial
Jonsson 1998 Randomised controlled trial. Did not meet our criteria for inclusion. Only ventilated infants whose pharyngeal
or tracheal cultures were positive for Ureaplasma urealyticum were randomised to treatment vs no treatment
Kicklighter 2001 Not a study of ventilated newborn infants
Krishnan 1995 Not a randomised controlled trial
Mandelli 1989 Not a study of newborns
Papoff 1997 Not a randomised controlled trial
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D A T A A N D A N A L Y S E S
Comparison 1. Antibiotics vs no antibiotics




participants Statistical method Effect size
1 Mortality 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2 Chronic Lung Disease (oxygen
requirement at 36 weeks)
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
Analysis 1.1. Comparison 1 Antibiotics vs no antibiotics, Outcome 1 Mortality.
Review: Prophylactic antibiotics to reduce morbidity and mortality in ventilated newborn infants
Comparison: 1 Antibiotics vs no antibiotics
Outcome: 1 Mortality
Study or subgroup Antibiotics Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Lyon 1998 4/34 8/41 0.60 [ 0.20, 1.83 ]
0.2 0.5 1 2 5
Favours antibiotics Favours control
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Analysis 1.2. Comparison 1 Antibiotics vs no antibiotics, Outcome 2 Chronic Lung Disease (oxygen
requirement at 36 weeks).
Review: Prophylactic antibiotics to reduce morbidity and mortality in ventilated newborn infants
Comparison: 1 Antibiotics vs no antibiotics
Outcome: 2 Chronic Lung Disease (oxygen requirement at 36 weeks)
Study or subgroup Antibiotics Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Lyon 1998 13/34 11/41 1.43 [ 0.74, 2.76 ]
0.5 0.7 1 1.5 2
Favours antibiotics Favours control
A D D I T I O N A L T A B L E S
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Table 1. Search methods for MEDLINE (Continued)
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Table 3. Search methods for CENTRAL (Continued)
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WH A T ’ S N E W
Last assessed as up-to-date: 6 December 2010.
Date Event Description
7 December 2010 New search has been performed This review updates the existing review “Prophylactic antibiotics to reduce
morbidity and mortality in ventilated newborn infants” published in the
Cochrane Database of Systematic Reviews (Inglis 2007).
One new trial was added to the excluded studies Ballard 2007.
No changes to conclusions.
The update in 2010 found no new trials for inclusion.
H I S T O R Y
Protocol first published: Issue 3, 2003
Review first published: Issue 1, 2004
Date Event Description
11 June 2008 Amended Converted to new review format.
14 March 2007 New search has been performed This review updates the existing review ’Prophylactic an-
tibiotics to reduce morbidity and mortality in ventilated
newborn infants’ , published in The Cochrane Library,
Issue 1, 2004 (Inglis 2004).
16Prophylactic antibiotics to reduce morbidity and mortality in ventilated newborn infants (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
An updated search in March 2007 identified one new
study for inclusion and seven studies that were not eli-
gible for inclusion.
The conclusions have not changed as a result of the in-
clusion of the new study
14 March 2007 New citation required but conclusions have not changed Substantive amendment
C O N T R I B U T I O N S O F A U T H O R S
Original Review:
GDI & MWD - searched for studies and assessed studies for inclusion
GDI - wrote the review
MWD - revised the review
Updated Review:
GDI & LAJ - searched for studies and assessed studies for inclusion
GDI - wrote the review
MWD & LAJ - revised the review
The November 2010 update was conducted centrally by the Cochrane Neonatal Review Group staff (Yolanda Montagne, Diane
Haughton, and Roger Soll). This update was reviewed and approved by GDI.
D E C L A R A T I O N S O F I N T E R E S T
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